Your browser doesn't support javascript.
loading
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.
Kurosawa, Saiko; Yamaguchi, Takuhiro; Mori, Ayako; Matsuura, Tomoko; Masuko, Masayoshi; Murata, Makoto; Tashiro, Haruko; Kako, Shinichi; Satake, Atsushi; Hagihara, Maki; Ota, Shuichi; Saito, Takeshi; Kagawa, Kumiko; Matsuo, Yayoi; Itonaga, Hidehiro; Uoshima, Nobuhiko; Yamaguchi, Hiroki; Naito, Kensuke; Takahashi, Miyako; Fukuda, Takahiro.
Afiliação
  • Kurosawa S; Department of Oncology, Ina Central Hospital, 1313-1 Koshiro-kubo, Ina, Nagano, 396-8555, Japan. skurosaw@inahp.jp.
  • Yamaguchi T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan. skurosaw@inahp.jp.
  • Mori A; Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Matsuura T; Nursing Division, National Cancer Center Hospital, Tokyo, Japan.
  • Masuko M; Nursing Division, National Cancer Center Hospital, Tokyo, Japan.
  • Murata M; Nursing Division, Fukuoka National Hospital, Fukuoka, Japan.
  • Tashiro H; Department of Hematopoietic Cell Therapy, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Kako S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Satake A; Department of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan.
  • Hagihara M; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Ota S; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Saito T; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Kagawa K; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Matsuo Y; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Itonaga H; Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
  • Uoshima N; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Yamaguchi H; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Naito K; Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
  • Takahashi M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Fukuda T; Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
J Cancer Surviv ; 17(3): 781-794, 2023 06.
Article em En | MEDLINE | ID: mdl-36048313
ABSTRACT

BACKGROUND:

Although rather favorable probabilities of return to work have been reported after allogeneic hematopoietic cell transplantation (allo-HCT), survivors often have difficulty continuing to work because of their immunocompromised status and diverse late effects after allo-HCT. We evaluated the incidence of and risk factors for recurrent sick leave in allo-HCT survivors after they initially returned to work.

METHODS:

We targeted allo-HCT survivors who were employed at diagnosis, aged 20-64 at survey, and survived for ≥ 2 years without relapse. Of the 1904 survivors who were informed of the study, 1148 returned the questionnaire (60%), and 1048 eligible participants were included in the overall analysis. In the present study that considered recurrent sick leave after return to work, we targeted 896 participants who returned to work at least once after allo-HCT. Participants stated if they had recurrent sick leave after returning to work and its reasons, as well as associated patient-, HCT/HCT center-, and work-related factors and clinical events after allo-HCT. A logistic regression analysis was conducted to explore correlated factors for recurrent sick leave.

RESULTS:

In survivors who returned to work, 30% required recurrent sick leave. The most frequent causes of recurrent leave were physical issues (72%), and analysis of free descriptions demonstrated that these were mainly associated with graft-versus-host disease, infection, or readmission. Other reasons included work-related issues such as gap between physical and working conditions. Multivariate analysis showed that cord blood transplantation, longer employment duration, and counseling from healthcare professionals were associated with a lower risk of recurrent leave. Readmission, immunosuppressant use, and symptoms involving the respiratory system, gut, and joints and muscles were associated with a higher risk.

CONCLUSIONS:

Our results drawn from a large cohort study should help healthcare professionals identify and assist at-risk patients. Multi-professional teams that provide continuous support and effective communication with the workplace are necessary to improve long-term outcomes after allo-HCT. IMPLICATIONS FOR CANCER SURVIVORS In order to continue working after the initial return to work, it is important to receive counseling from healthcare professionals and obtain reasonable accommodation from workplace.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Sobreviventes de Câncer Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Sobreviventes de Câncer Idioma: En Ano de publicação: 2023 Tipo de documento: Article